XNASIRTC
Market cap3.06bUSD
Jan 10, Last price
97.70USD
1D
5.05%
1Q
71.19%
Jan 2017
225.67%
IPO
278.83%
Name
iRhythm Technologies Inc
Chart & Performance
Profile
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 492,681 19.90% | 410,921 27.29% | |||||||
Cost of revenue | 221,119 | 175,899 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 271,562 | 235,022 | |||||||
NOPBT Margin | 55.12% | 57.19% | |||||||
Operating Taxes | 750 | 269 | |||||||
Tax Rate | 0.28% | 0.11% | |||||||
NOPAT | 270,812 | 234,753 | |||||||
Net income | (123,406) 6.24% | (116,155) 14.60% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8,820 | 13,182 | |||||||
BB yield | -0.27% | -0.47% | |||||||
Debt | |||||||||
Debt current | 30,318 | 13,031 | |||||||
Long-term debt | 209,539 | 214,110 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,012 | 1,307 | |||||||
Net debt | 103,093 | 13,997 | |||||||
Cash flow | |||||||||
Cash from operating activities | (50,101) | (23,012) | |||||||
CAPEX | (40,424) | (29,830) | |||||||
Cash from investing activities | (1,209) | (52,434) | |||||||
Cash from financing activities | 8,820 | 26,716 | |||||||
FCF | 230,844 | 240,295 | |||||||
Balance | |||||||||
Cash | 133,764 | 213,144 | |||||||
Long term investments | 3,000 | ||||||||
Excess cash | 112,130 | 192,598 | |||||||
Stockholders' equity | (645,687) | (522,568) | |||||||
Invested Capital | 1,001,779 | 892,337 | |||||||
ROIC | 28.60% | 27.68% | |||||||
ROCE | 76.26% | 63.56% | |||||||
EV | |||||||||
Common stock shares outstanding | 30,528 | 29,916 | |||||||
Price | 107.04 14.27% | 93.67 -20.41% | |||||||
Market cap | 3,267,717 16.61% | 2,802,205 -18.82% | |||||||
EV | 3,370,810 | 2,816,202 | |||||||
EBITDA | 293,706 | 254,631 | |||||||
EV/EBITDA | 11.48 | 11.06 | |||||||
Interest | 3,650 | 4,138 | |||||||
Interest/NOPBT | 1.34% | 1.76% |